Second, the designed stapled peptide, SAH-mAH2-5, exhibited profound anti-pancreatic cancer effects, especially in Notch1-hyperactivated pancreatic cancer, in multiple preclinical models. This evidence concerns the gene NOTCH1 and pancreatic neoplasm.